Company

Pinteon Therapeutics

Biotechnology Research 3 employees

Employees: 3
Contacts: 3
Emails: 3
Phones: 1

LinkedIn Crunchbase

Pinteon Therapeutics Overview

Industry: Biotechnology Research
Employees: 3
Funding: 29.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Kinnear Pharmaceuticals

About Pinteon Therapeutics

Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.

Pinteon Therapeutics Contact Details

People in AeroLeads: 3
With contact data: 3
Email contacts: 3; 100.0% coverage
Phone contacts: 1; 33.3% coverage

Pinteon Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Kun Ping Lu	Professor, Harvard Medical School	Newton Centre, Massachusetts, United States	Email
Kim Mcclure	Medicinal Chemist	United States	Email
Michael Ahlijanian	Biopharma Executive: Neuroscience Drug	Madison, Connecticut, United States	Email Phone